Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic’s SynchroMed II Infusion Pain Treatment Proves Cost-Effective In Study

Executive Summary

A new cost-effectiveness study shows cancer patients using targeted drug delivery with Medtronic’s SynchroMed II infusion system and conventional medical management incur lower overall health care costs than patients using conventional medical management alone.

Advertisement

Related Content

Starts & Stops: Boston Scientific Launches New Lotus TAVR Trial, Medtronic Starts Study Of SynchroMed II Pain Pump
SISTERS Data Could Lift Medtronic's SynchroMed II From Recall Repercussions

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT124918

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel